Dyadic International Inc, DE Dossier - Source-backed chat

Dyadic International Inc, DE

DYAINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.43Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $17.2M

Enterprise Value $20.8M

Shares Outstanding 39M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Dyadic International, Inc. (d/b/a Dyadic Applied BioSolutions) is executing a critical strategic pivot from a pure-play technology platform developer to a commercially driven provider of animal-free recombinant proteins and enzymes. While the company's proprietary C1 and Dapibus expression systems offer significant advantages in speed, yield, and cost-efficiency, Dyadic remains pre-profitability and faces immediate regulatory headwinds. The company recently received a Nasdaq delisting warning due to its share price falling below the $1.00 minimum and its stockholders' equity dropping into negative territory ($407,732 as of Q1 2026). Although commercial launches like AlbuFree™ DX and partnerships with Fermbox Bio and Proliant provide long-term upside, the near-term delisting risk and going-concern uncertainties warrant a cautious Hold recommendation until capital structure and listing compliance are stabilized.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$5.50

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

Commercial adoption of newly launched recombinant proteins is slower than expected, and R&D revenues flatline. The company fails to satisfy Nasdaq's listing requirements or secure a listing extension, leading to delisting to the OTC markets. Going-concern risks materialize as cash reserves dwindle, forcing highly dilutive equity financing or restructuring of the $5.09 million outstanding senior secured convertible notes under unfavorable terms.

Base CaseCentral scenario

$1.5050%

Dyadic continues to grow its top-line revenue through R&D collaborations and early-stage commercial product sales, matching consensus expectations of ~$6.79 million for FY 2026. The company requests a Nasdaq hearing and implements a reverse stock split to maintain its listing. Cash burn is managed carefully with the remaining $6.6 million in cash and securities, but the company remains unprofitable through 2026, with breakeven pushed to late 2027.

Bull CaseUpside scenario

$3.0030%

The commercial launch of AlbuFree™ DX and recombinant bovine transferrin gains rapid market traction in the cultivated meat and life sciences sectors, driving high-margin profit-share revenues. Concurrently, the company successfully executes a reverse stock split to regain Nasdaq compliance, and outstanding convertible notes are converted to equity, resolving the negative equity position. Strong revenue growth from Gates Foundation and CEPI-funded programs accelerates the path to profitability by 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary C1 and Dapibus expression platforms offer high-yield, low-cost, and rapid production of complex proteins compared to traditional mammalian cell lines.
Strategic shift to non-pharmaceutical ancillary proteins reduces regulatory hurdles and shortens the timeline to commercial revenue generation.
Established commercial partnerships with industry leaders such as Proliant Health & Biologicals, Fermbox Bio, and BRIG Bio.
Strong backing and validation from global organizations, including the Bill & Melinda Gates Foundation and CEPI.

Key Investment Risks

Immediate risk of delisting from the Nasdaq Capital Market due to non-compliance with the $1.00 minimum bid price and $2.5 million stockholders' equity rules.
History of operating losses and negative stockholders' equity ($407,732 as of March 31, 2026), raising going-concern uncertainties.
High concentration of debt with $5.09 million in outstanding 8.0% senior secured convertible notes maturing in 2027.
Dependence on third-party partners for the successful commercialization, distribution, and marketing of its co-developed products.

Thesis Invalidation Triggers

Failure to secure a Nasdaq listing extension or successfully execute a reverse stock split, resulting in delisting to OTC markets.
A significant drop in cash and investment-grade securities below $3.0 million without a clear path to non-dilutive funding.
Termination or material delay of key commercial agreements, particularly the Proliant AlbuFree™ DX profit-sharing partnership.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.